ArticleFrontiers in pharmacology2026
MOG-Ab-associated optic neuritis with concurrent GFAP-Ab positivity following tislelizumab-based treatment: a case report.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the clinical characteristics and therapeutic management of myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-related optic neuritis (ON), a rare neurological immune-related adverse event (irAE) associated with the programmed death-1 (PD-1) inhibitor tislelizumab. Methods: We report a retrospective case of a 48-year-old male patient with extensive-stage small cell lung cancer (ES-SCLC) who developed acute bilateral vision loss after receiving the first dose of tislelizumab combined with chemotherapy. After admission to the neurology department and a systematic clinical evaluation, the patient was found to be positive for both MOG-Ab and glial fibrillary acidic protein antibody (GFAP-Ab). He was ultimately diagnosed with MOG-Ab-associated ON with Concurrent GFAP-Ab Positivity. Results: Following diagnosis, tislelizumab was promptly discontinued. The patient received high-dose methylprednisolone (1,000 mg/d) as initial therapy, followed by sequential tapering combined with rituximab for immunomodulation. This regimen resulted in considerable visual recovery. In subsequent treatment lines, immune checkpoint inhibitors (ICIs) were avoided. Conclusion: This case underscores the potential of PD-1 inhibitors to trigger rare MOG-Ab-associated ON. For such vision-threatening irAEs, early recognition, immediate ICI withdrawal, multidisciplinary collaboration, and aggressive immunosuppressive therapy are essential for reversing neurological impairment and improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.